Downstream Processing Featured Articles

41. The Real Threat To Biopharma Supply Chains: Bioprocessing Materials 5/12/2020

    The COVID-19 induced risk to biopharma is not a shortage of pharmaceutical ingredients. It’s the constricting supply of consumable materials and equipment necessary to produce therapies from them. Mike Piccarreta, Partner at Kearney, offers an outlook and practical advice on supply stabilization in this BioProcess Online exclusive. 

42. One-Touch Single-Use Fluid Path Assemblies Enhance Operational Flexibility 10/5/2009
    Meissner’s One-Touch single-use fluid path assemblies are designed for secure fluid transfer in critical biopharmaceutical processing applications. The assemblies reduce process risk while providing an enhanced level of convenience that maximizes flexibility in the deployment of singleuse systems, as well as conventional systems.
43. Success Of Engineered Tissue Depends On Where It's Grown 8/14/2012

    Tissue implants made of cells grown on a sponge-like scaffold have been shown in clinical trials to help heal arteries scarred by atherosclerosis and other vascular diseases. However, it has been unclear why some implants work better than others. By Anne Trafton

44. Advion Announces Full Integration With Agilent Technologies Liquid Chromatography Systems 12/10/2012

    Advion, Inc., a leading life sciences Systems and Consumables developer, announces that its expression compact mass spectrometer (CMS) is now fully integrated with Agilent Technologies’ full range of HPLC and (U)HPLC liquid chromatography systems.

45. Scientists Show Protein-Making Machinery Can Switch Gears With A Small Structural Change 11/15/2012

    For the past several years, Min Guo, an assistant professor at The Scripps Research Institute (TSRI), has focused on the intricate actions of an ancient family of catalytic enzymes that play a key role in translation, the process of producing proteins.

46. FDA Approves New Seasonal Influenza Vaccine Made Using Novel Technology 1/16/2013

    The U.S. Food and Drug Administration recently announced that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age.

47. NIH-Funded Researchers Create Next-Generation Alzheimer's Disease Model 4/9/2013

    A new genetically engineered lab rat that has the full array of brain changes associated with Alzheimer’s disease supports the idea that increases in a molecule called beta-amyloid in the brain causes the disease, according to a study, published in the Journal of Neuroscience.

48. Study Points To Possible Cause Of, And Treatment For, Non-Familial Parkinson's 2/6/2013

    Columbia University Medical Center (CUMC) researchers have identified a protein trafficking defect within brain cells that may underlie common non-familial forms of Parkinson’s disease.

49. Biotest Pharmaceuticals Announces Strategic Long-Term Manufacturing, Supply And License Agreement 1/10/2013

    Biotest Pharmaceuticals Corp. (BPC), a wholly owned U.S. subsidiary of Biotest AG (Dreieich, Germany), recently announced it has entered into a strategic long-term manufacturing, supply, and license agreement with ADMA Biologics,Inc.(ADMA).

50. RNA-Based Therapy Brings New Hope For An Incurable Blood Cancer 10/10/2012

    Three thousand new cases of Mantle Cell Lymphoma (MCL), a form of blood cancer, appear in the United States each year. With a median survival span of only five to seven years, according to the Leukemia and Lymphoma Society, this disease is devastating, and new therapies are sorely needed.